Welcome to our dedicated page for Tarsus Pharmaceuticals SEC filings (Ticker: TARS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, with AI-powered tools to help interpret them. Tarsus is a commercial-stage biopharmaceutical company focused on therapeutics starting with eye care, led by XDEMVY (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis and a lotilaner-based pipeline that includes TP-04 and TP-05.
Through this page, users can access Tarsus’ current and historical filings, including annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically describe the company’s business, risk factors, financial statements, and discussion of results. Current reports on Form 8-K provide details on material events such as quarterly financial results, annual meeting outcomes, and other significant corporate developments. For example, recent 8-K filings reference press releases that set forth Tarsus’ results of operations for specific quarters and describe shareholder voting results at the annual meeting.
Investors can also review proxy statements referenced in 8-K filings to understand proposals submitted to stockholders, including director elections, advisory votes on executive compensation, and ratification of the independent registered public accounting firm. In addition, Form 4 insider transaction reports, when available, can be used to track purchases and sales of TARS shares by directors, officers, and other insiders.
Stock Titan’s AI features summarize lengthy filings, highlight key sections related to revenue dependence on XDEMVY, pipeline development, capital needs, and risk factors, and explain technical language in more accessible terms. Real-time updates from EDGAR ensure that new Tarsus filings, from 10-K and 10-Q reports to 8-K current reports and Form 4 insider filings, appear promptly so users can follow changes in the company’s regulatory and financial profile without manually parsing every document.
Dianne C. Whitfield filed a Form 144 reporting proposed sales of Common Stock. The filing lists three transactions: 15,565 shares on 01/02/2026 (proceeds $1,255,687.45), 4,029 shares on 03/17/2026 (proceeds $279,671.82), and 4,071 shares on 03/18/2026 (proceeds $279,717.60).
The broker on the notice is Fidelity Brokerage Services LLC. The filing includes a separate line noting Restricted Stock Vesting dated 03/18/2026.
TARS filed a Form 144 reporting proposed sale of 4,231 shares of Common Stock. The filing also records recent dispositions by Bryan Wahl of 4,084 shares on 03/17/2026 and 4,125 shares on 03/18/2026, with dollar entries of 283,489.63 and 283,427.93 respectively.
The notice lists a brokerage holder, Fidelity Brokerage Services LLC, and identifies a 03/18/2026 restricted stock vesting classified as Compensation. This Form 144 is a routine disclosure of intended resale under Rule 144 and related recent insider dispositions.
TARS filed a Form 144 reporting proposed sales of Common Stock by a reporting person. The filing lists 4,589 shares to be sold following a restricted stock vesting on 03/18/2026 as compensation. It also discloses prior sales in March: 8,366, 3,125, and 3,610 shares with associated proceeds reported.
TARS reported a Rule 144 notice for the proposed sale of 390 shares of Common Stock tied to a restricted stock vesting on 03/18/2026. The filing lists prior short-term transactions by Elizabeth Yeu-Lin: 375 shares on 03/17/2026 and 379 shares on 03/18/2026.
The filing identifies Fidelity Brokerage Services LLC as the broker and labels the 390-share entry as compensation-related (restricted stock vesting). This notice is an administrative disclosure of an intended resale under Rule 144.
Dianne C. Whitfield filed a Form 144 notice to sell 4,071 shares of Common Stock. The shares are tied to restricted stock vesting dated 03/17/2026 and are listed with Fidelity Brokerage Services LLC as broker. The filing also discloses prior dispositions of 15,565 shares on 01/02/2026 and 4,029 shares on 03/17/2026.
Bryan Wahl filed a Form 144 to offer 4,125 shares of Common Stock. The filing links the shares to a restricted stock vesting event dated 03/17/2026 and lists Fidelity Brokerage Services LLC as the broker. The filing also shows recent activity of 4,084 shares sold on 03/17/2026 and includes adjacent amounts $283,427.93 and $283,489.63.
Bobak Azamian reports proposed sale of common stock under Rule 144. The filing lists 11,667 common shares associated with Fidelity Brokerage Services LLC on 03/18/2026. The filing also discloses a prior sale of 10,972 shares on 03/17/2026 for $761,618.09.
The securities to be sold are listed as resulting from restricted stock vesting and are labeled compensation on 03/17/2026. Timing and exact sale methods are not detailed in the excerpt.
TARS disclosed notices under Rule 144 for transactions in its common stock. The filing lists a Restricted Stock Vesting entry of 3,610 shares dated 03/17/2026 attributed to Fidelity Brokerage Services LLC as compensation. The filing also records sales by Seshadri Neervannan of 8,366 shares on 03/04/2026 and 3,125 shares on 03/17/2026, with proceeds shown alongside each sale.
TARS files a Form 144 notice to sell 2,133 shares of Common Stock following restricted stock vesting on 03/17/2026.
The filing shows the shares are tied to compensation (restricted stock vesting). The excerpt also reports that Jeffrey Farrow sold 2,111 shares on 03/17/2026. Trading venue is listed as NASDAQ.
Aziz A. Mottiwala reports an intention to sell Common stock. The filing lists 4,330 shares of Common stock to be sold in connection with restricted stock vesting tied to compensation, with the action dated 03/17/2026 and the security shown on NASDAQ.
The filing also reports 4,286 shares of Common stock sold during the prior three months, dated 03/17/2026. The entries identify a brokerage address for Fidelity Brokerage Services LLC.